Cancers, Volume 14, Issue 5
2022 March-1 - 262 articles
Cover Story: In the last decade, many therapeutic options have been approved, improving survival outcomes in advanced prostate cancer (PCa) patients. The emphasis on immune checkpoint inhibitors (ICIs) has led to many trials in this setting, with generally poor results. We discuss the immunobiology of PCa, the current clinical data, and ongoing trials to understand the potential role of ICIs in this disease and the patients’ subset more likely to benefit from them. Current evidence shows the tumor microenvironment (TME) needs a qualitative evaluation, and the prognostic/predictive role of immunotherapy biomarkers needs further assessment in PCa. ICI monotherapy has shown modest efficacy, while combined strategies with other standard therapies have shown some results. ICIs in biomarker-selected patients and new targets modulating the immune TME should be better investigated. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.